These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 18194823

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Amyopathic dermatomyositis--an uncommon presentation of dermatomyositis.
    Arnson Y, Dovrish Z, Hadari R, Amital H.
    Isr Med Assoc J; 2007 Jun; 9(6):492-3. PubMed ID: 17642406
    [No Abstract] [Full Text] [Related]

  • 3. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Lee SS, Park YW, Park JJ, Kang YM, Nam EJ, Kim SI, Lee JH, Yoo WH, Lee SI.
    Scand J Rheumatol; 2009 Jun; 38(1):11-4. PubMed ID: 19191187
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Early-stage testicular cancer: a rare association with dermatomyositis.
    Tan E, Young D, McLaren B, Wright A.
    Australas J Dermatol; 2010 May; 51(2):139-41. PubMed ID: 20546223
    [Abstract] [Full Text] [Related]

  • 8. [Methotrexate combined with leflunomide or hydroxychloroquine in the treatment of rheumatoid arteritis].
    Zhang X, Cui Y, Luo rQ, Yao RY, Zhou H.
    Zhonghua Yi Xue Za Zhi; 2004 Jun 17; 84(12):1038-40. PubMed ID: 15312543
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of leflunomide as an adjuvant drug in refractory dermatomyositis with primarily cutaneous activity.
    de Souza RC, de Souza FHC, Miossi R, Shinjo SK.
    Clin Exp Rheumatol; 2017 Jun 17; 35(6):1011-1013. PubMed ID: 28422003
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy.
    Lou T, Wang C, Chen Z, Shi C, Tang H, Liu X, Yin P, Yu X.
    Nephrology (Carlton); 2006 Apr 17; 11(2):113-6. PubMed ID: 16669971
    [Abstract] [Full Text] [Related]

  • 18. Dermatomyositis and Graves' disease.
    Selva-O'Callaghan A, Mijares-Boeckh-Behrens T, Solans-Laque R, Molins-Vara T, Olivé G, Vilardell-Tarrés M.
    Clin Exp Rheumatol; 2001 Apr 17; 19(5):595-6. PubMed ID: 11579725
    [No Abstract] [Full Text] [Related]

  • 19. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases.
    Dold S, Justiniano ME, Marquez J, Espinoza LR.
    Clin Rheumatol; 2007 Jul 17; 26(7):1186-8. PubMed ID: 16736125
    [Abstract] [Full Text] [Related]

  • 20. Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center.
    Femia AN, Eastham AB, Lam C, Merola JF, Qureshi AA, Vleugels RA.
    J Am Acad Dermatol; 2013 Oct 17; 69(4):654-7. PubMed ID: 24034377
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.